AdAlta Limited (ASX:1AD) is a clinical-stage biotechnology company using its i-body platform to discover and develop next-generation protein therapeutics addressing drug targets that are challenging for other technologies. AdAlta"s i-body technology goes where traditional antibody drugs cannot. AdAlta"s east-to-west immunotherapy strategy aims to bring hope to solid cancer patients who have seen what CAR-T cell therapy can do for blood cancers (new subsidiary AdCella) and to lung fibrosis patients whose diagnosis is a death sentence today (AD-214 in Phase II).
